Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis.

Bowen, J D; Petersdorf, S H; Richards, T L; Maravilla, K R; Dale, D C; Price, T H; St John, T P; Yu, A S

Bowen, J D; Petersdorf, S H; Richards, T L; Maravilla, K R; Dale, D C; Price, T H; St John, T P; Yu, A S.

Affiliation

Bowen JD; Department of Neurology, University of Washington, Seattle, USA.

Clin Pharmacol Ther ; 64(3): 339-46, 1998 Sep.

Article in En | MEDLINE | ID: mdl-9757158

Subject(s)

Antibodies, Monoclonal/therapeutic use; CD11 Antigens/immunology; CD18 Antigens/immunology; Multiple Sclerosis/therapy; Adult; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal/blood; Antibodies, Monoclonal/pharmacokinetics; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukocytes/drug effects; Lymphocytes/drug effects; Male; Middle Aged; Multiple Sclerosis/immunology; Time Factors; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: CD18 Antigens / CD11 Antigens / Antibodies, Monoclonal / Multiple Sclerosis Type of study: Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Clin Pharmacol Ther Year: 1998 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links